Vancouver, Canada

Dustin Bleile

USPTO Granted Patents = 1 


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Mind of Dustin Bleile

Introduction

Dustin Bleile, an accomplished inventor based in Vancouver, Canada, has made significant contributions to the field of biotechnology. With a focus on antibody therapeutics, his work embodies the spirit of innovation that drives progress in medical science.

Latest Patents

Bleile holds a noteworthy patent titled "Antibodies with enhanced or suppressed effector function." This innovation involves the development of rationally designed antibodies and polypeptides that incorporate multiple Fc region amino acid substitutions. These modifications synergistically enhance selectivity and binding affinity to target Fc receptors, offering a greater effectiveness in therapeutic applications compared to wild-type Fc components.

Career Highlights

Currently, Bleile is an integral part of Zymeworks Inc., a company that specializes in the development of innovative biotherapeutics. His role allows him to leverage his expertise in antibody design to advance products that have the potential to change the landscape of treatment options for various diseases.

Collaborations

At Zymeworks, Bleile collaborates with talented colleagues such as Igor D'Angelo and Stacey A. L. Tom-Yew. Their collective efforts foster an environment of creativity and drive, pushing the boundaries of what is possible in the realm of biopharmaceuticals.

Conclusion

Dustin Bleile's work exemplifies the essence of innovation in biotechnology. His advancements in antibody therapeutics not only reflect his ingenuity as an inventor but also highlight the collaborative efforts that are essential in the development of groundbreaking medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…